Personalized antibiotic treatment decisions in hours, not days.
Welcome to CytoSPAR. We're at the forefront of transforming healthcare diagnostics for complicated Urinary Tract Infections (cUTI) with BLAST (Bacteria Labeling Antibiotic Susceptibility Test). This next-generation Antibiotic Susceptibility Test AST represents a significant leap forward, enabling healthcare professionals to swiftly identify the most effective antibiotic treatments. This innovation enhances patient care and improves outcomes.
BLAST redefines antibiotic susceptibility testing with its rapid, precise, and groundbreaking methodology. By analyzing antibiotic sensitivity directly from urine samples, BLAST delivers results in 5 hours, facilitating same-day therapeutic decisions. This innovative system integrates seamlessly into laboratory workflows, simplifying operations while maintaining high accuracy and reliability.
BLAST is for Research Use Only and has not been Cleared or Approved by the US Food and Drug Administration.
Leveraging advanced bacterial labeling technology, BLAST observes real-time bacterial responses to a broad spectrum of antibiotics, surpassing traditional testing speeds and accuracy.
BLAST's technology eliminates the need for a bacterial growth phase, delivering comprehensive resistance profiles in 5 hours—a stark improvement over the conventional 24-72 hour timeframe.
BLAST is currently for Research Use Only and has not been Cleared or Approved by the US Food and Drug Administration.
At CytoSPAR, our BLAST system streamlines the treatment of urinary tract infections (UTIs) and other bacterial infections, ensuring a faster and more efficient recovery. Here’s a simplified explanation of how it works:
BLAST is for Research Use Only and has not been Cleared or Approved by the US Food and Drug Administration.
A minimal urine sample is all it takes to start. This process is designed to be fast and patient-friendly, ensuring ease and efficiency from the very beginning.
Our innovative technology swiftly analyzes bacteria's response to antibiotics directly from your urine sample. This rapid and accurate assessment allows for immediate treatment decisions, significantly outpacing traditional testing methods.
No Bacterial Growth Phase Required. BLAST delivers actionable antibiotic susceptibility results in just 5 hours, eliminating the need for a bacterial growth phase, a groundbreaking advancement compared to the 24-72 hours required by traditional methods.
BLAST delivers actionable antibiotic susceptibility results in just 5 hours, eliminating the need for a bacterial growth phase, a groundbreaking advancement compared to the 24-72 hours required by traditional methods.
Precisely identifies the most effective antibiotics, reducing trial and error.
Starts the right antibiotic early, lowering the risk of infection return.
Enables ongoing adjustment of treatments for optimal outcomes.
Minimizes unnecessary antibiotic exposure, minimizing potential side effects.
Offers a straight forward, non-invasive testing experience for patients and providers.
Delivers results within 5 hours, expediting treatment initiation.
Aids in the global battle against antibiotic resistance by promoting appropriate antibiotic use.
CytoSPAR BLAST sets a new benchmark in antibiotic susceptibility testing, dramatically enhancing the speed, efficiency, and accuracy of diagnostics. This leap forward ensures healthcare providers can make quicker, more informed treatment decisions, significantly improving patient care and outcomes in the fight against infectious diseases and antimicrobial resistance.
